Urinary Bladder Cancer begins when cells in the urinary bladder start to grow uncontrollably.
The bladder is a hollow organ in the lower abdomen (pelvis), which collects and stores urine produced by the kidneys. It is estimated that there are 383,000 cases of bladder cancer worldwide out of which they are most commonly found in industrialised countries. Bladder cancer occurs mostly among older individuals although it has been noted to appear among the younger age groups as well. The average age of diagnosis is in the 60s. The cancer has a high rate of recurrence.
Bladder cancer is a type of malignancy arising from the epithelial lining (i.e., the urothelium) of the urinary bladder. It is a disease in which abnormal cells multiply without control in the bladder. The most common type of bladder cancer recapitulates the normal histology of the urothelium and is known as transitional cell carcinoma or more properly urothelial cell carcinoma.
Lack of awareness about bladder cancer risk factors and warning signs is costing lives. Approximately 70-75% of cases at the time of diagnosis are non-invasive or superficial tumours. These are not usually life-threatening, but difficult and costly to treat because they often come back. Life-long follow up is needed.
The remaining 20% of people with bladder cancer are diagnosed with invasive tumours. Bladder removal is still considered the best option for a cure. Funding for bladder cancer is among the lowest, while the cost of treating the disease is among the highest of all cancers due to its good prognosis and the need for life-long follow up.
Quitting smoking has been shown to decrease the risk, though not as much as if one never smoked. For those with high-risk jobs that expose people to harmful chemicals, screening might prove to be worth the investment.
Women are all too often misdiagnosed and are twice as likely as men to die from the disease. Blood in the urine is most common symptom of bladder cancer and is often mistaken, ignored or not taken seriously enough by gynaecologists and women themselves. Other negative prognosis factors are a higher proportion of rare cell types found and the amount of women diagnosed with the more serious, invasive bladder cancer at later stages. Studies are suggesting that women may actually be more susceptible to the bladder carcinogens in cigarette smoke and perhaps other risk factors as well.
Early stage tumour may not give any symptoms. Common symptoms of bladder cancer include:
These symptoms are not sure signs of bladder cancer. Infections, benign tumours, bladder stones or other problems also can cause these symptoms. Anyone with these symptoms should see a doctor so that the doctor can diagnose and treat any problem as early as possible. If there is blood in the urine, then one should be careful and should not neglect it.
Like all cancers, bladder cancer is most likely to be successfully treated if detected early, when it is small and has not invaded surrounding tissues.
Screening tests are usually performed periodically, for example, once a year or once every five years. The most widely used screening tests are medical interview, physical examination, urinalysis, urine cytology, ultrasonography and cystoscopy
The choice of treatment depends on the type of tumour and the stage of disease when it is found; however, age, health, and personal preferences are also factors.
Primary radiation therapy generally involves a radiation dose of 6,000 to 7,000 rad to the bladder in patients not fit or not willing to undergo surgery
Chemotherapy used to treat bladder cancer can be either local or systemic.
BCG is the most commonly prescribed immunotherapeutic agent for use in bladder cancer treatment to prevent recurrences in superficial bladder cancer.
Treatment options depend on the stage of bladder cancer. Three types of standard treatment are used, as follows:
|Survival Rate||85-90 per cent|
|Morbidity||6-12 per cent|
We, at our hospital, have uro-oncology service comprising of experienced Uro-Onco Surgeon who performs open, laparoscopic and robotic surgery trained at Prestigious Tata Memorial Hospital, Mumbai and have dedicated Radiation, Medical Oncologist and Onco Pathologist. In addition we have state-of-the-art technology including Da Vinci Robot, IMRT and IGRT, specialised stoma management team, and Pain and Palliative Medicine department. We are committed to provide highest internationally accepted evidence based management for urological cancers under one roof.